Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins to Offer GE's Cardiomyocytes in Toxicity Screening Services

NEW YORK (GenomeWeb News) — Eurofins said today that its Panlabs pharmacology services arm has signed an agreement with GE Healthcare giving it the exclusive right to offer GE's Cytiva cardiomyocytes for cardiotoxicity screening services.

Cardiomyocytes offer a cost-effective and time-efficient alternative to animal models for predictive cardiotoxicity testing in drug discovery and development, Eurofins said.

Eurofins said that the initial range of cardiotoxicity screening services covered by the deal will be expanded during the term of the agreement, but did not elaborate.